Twinstrand Therapeutics Announces US FDA Approval Of Its IND Application For Clinical Development Of TST10088
10/19/2005 5:09:02 PM
BURNABY, B.C., July 27 /CNW/ - Twinstrand Therapeutics Inc. (Twinstrand)
today announced that the United States Food and Drug Administration (US FDA)
has approved its Investigational New Drug (IND) application for the clinical
development of TST10088; a novel, proprietary and targeted prodrug being
developed for the treatment of solid tumor forms of cancer.
comments powered by